These results suggest that HCQ or FIN, and particularly in combination, effectively inhibit ERK1/2, EGFR, and STAT3 signaling pathways, which may contribute to their therapeutic potential in BPH management. Here, STAT3 is linked to benign prostatic hyperplasia.